Immunoglobulin-mediated membranoproliferative glomerulonephritis
MONDO:0014005Glomerulonephritis characterized by mesangial proliferation, endocapillary proliferation, and glomerular capillary wall remodeling with immune complex deposits from classical complement pathway activation.
Also known as: Ig-mediated MPGN, Ig-mediated membranoproliferative glomerulonephritis, NPHS7, immune complex mediated membranoproliferative glomerulonephritis, immunoglobulin-mediated MPGN, immunoglobulin-mediated membranoproliferative glomerulonephritis, membranoproliferative glomerulonephritis type I, mesangiocapillary glomerulonephritis type 1
19 clinical trials for this condition and its sub-types, 12 tagged with Immunoglobulin-mediated membranoproliferative glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug hope for rare kidney disease: daratumumab trial launches
Disease control OngoingThis study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a single injection drug calm the immune attack on kidneys?
Disease control OngoingThis phase 2 trial tests an experimental drug called SGB-9768 in adults with three related kidney diseases: IgA nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. These conditions occur when the immune system deposits proteins in…
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control ApprovedThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC